Abstract
Mutations in the von Hippel-Lindau (VHL) tumour-suppressor gene result in several forms of cancer. In the present study, we investigated the role of VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/ΔNES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berra E, Roux D, Richard DE and Pouyssegur J . (2001). EMBO Rep., 2, 615–620.
Bonicalzi ME, Groulx I, de Paulsen N and Lee S . (2001). J. Biol. Chem., 276, 1407–1416.
Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ and Maher ER . (2001). Hum. Mol. Genet., 10, 1029–1038.
Clifford SC and Maher ER . (2000). Adv. Cancer Res., 82, 85–105.
Davidowitz EJ, Schoenfeld AR and Burk RD . (2001). Mol. Cell. Biol., 21, 865–874.
Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM and Klausner RD . (1995). Science, 269, 1402–1406.
Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS and Arbeit JM . (2001). Genes Dev., 15, 2520–2532.
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ and Ratcliffe PJ . (2001). Cell, 107, 43–54.
Groulx I and Lee S . (2002). Mol. Cell. Biol., 22, 5319–5336.
Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M and Kaelin Jr W . (2001). Hum. Mol. Genet., 10, 1019–1027.
Huang J, Zhao Q, Mooney SM and Lee FS . (2002). J. Biol. Chem., 277, 39792–39800.
Ivan M and Kaelin Jr W . (2001). Curr. Opin. Genet. Dev., 11, 27–34.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin Jr W . (2001). Science, 292, 464–468.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW and Ratcliffe PJ . (2001). Science, 292, 468–472.
Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin Jr W, Linehan WM, Klausner RD, Gnarra JR and Vande Woude GF . (1999). Mol. Cell. Biol., 19, 5902–5912.
Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM and Klausner RD . (1996). Proc. Natl. Acad. Sci. USA, 93, 1770–1775.
Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis GN and Klausner RD . (1999). Mol. Cell. Biol., 19, 1486–1497.
Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin Jr W and Iliopoulos O . (1998). Mol. Cell, 1, 959–968.
Pause A, Lee S, Lonergan KM and Klausner RD . (1998). Proc. Natl. Acad. Sci. USA, 95, 993–998.
Roberts BJ and Whitelaw ML . (1999). J. Biol. Chen., 274, 36351–36356.
Ruoslahti E . (1999). Adv. Cancer Res., 76, 1–20.
Tanimoto K, Makino Y, Pereira T and Poellinger L . (2000). EMBO J., 19, 4298–4309.
Acknowledgements
This work was supported in part by the National Health and Medical Research Council of Australia, Project Grant No. 10365, awarded to BJ Roberts. We also acknowledge the assistance of the Whitelaw laboratory (School of Molecular Life Sciences, University of Adelaide) in providing several plasmids used in this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lewis, M., Roberts, B. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein. Oncogene 22, 3992–3997 (2003). https://doi.org/10.1038/sj.onc.1206683
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206683
Keywords
This article is cited by
-
High nuclear expression of HIF1α, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence
Journal of Cancer Research and Clinical Oncology (2021)
-
VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2
Nature Communications (2017)
-
K63-Ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair
Oncogene (2014)
-
pVHL-Mediated Transcriptional Repression of c-Myc by Recruitment of Histone Deacetylases
Molecules and Cells (2012)
-
Von Hippel-Lindau syndrome: molecular mechanisms of the disease
Clinical and Translational Oncology (2010)